CRISM Therapeutics Corporation
CRTX.L · LSE
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | £0 | – | £0 | £0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | £4 | – | £20 | £0 |
| Gross Profit | -£4 | – | -£20 | £0 |
| % Margin | – | – | – | – |
| R&D Expenses | £0 | – | £0 | £0 |
| G&A Expenses | £1,242 | – | £380 | £1 |
| SG&A Expenses | £1,242 | – | £380 | £293 |
| Sales & Mktg Exp. | £0 | – | £0 | £292 |
| Other Operating Expenses | £0 | – | -£377 | £0 |
| Operating Expenses | £1,242 | – | £3 | £293 |
| Operating Income | -£1,246 | – | -£3 | -£293 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | £0 | – | -£14 | -£133 |
| Pre-Tax Income | -£1,246 | – | -£16 | -£426 |
| Tax Expense | £0 | – | -£0 | -£56 |
| Net Income | -£1,276 | – | -£16 | -£422 |
| % Margin | – | – | – | – |
| EPS | -0.038 | – | -0.002 | 0.23 |
| % Growth | – | – | -100.9% | – |
| EPS Diluted | -0.038 | – | -0.002 | 0.23 |
| Weighted Avg Shares Out | 33,470 | – | 6,080 | 8,713 |
| Weighted Avg Shares Out Dil | 32,678 | – | 6,076 | 8,713 |
| Supplemental Information | – | – | – | – |
| Interest Income | £0 | – | £0 | £0 |
| Interest Expense | £0 | – | £0 | £0 |
| Depreciation & Amortization | £11 | – | £10 | -£1 |
| EBITDA | -£1,235 | – | £6 | -£293 |
| % Margin | – | – | – | – |